A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense Continuous Glucose Monitoring Devices in a Home-Use Study of Subjects with Type 1 Diabetes

2020 ◽  
Vol 22 (11) ◽  
pp. 846-852
Author(s):  
Rabab Z. Jafri ◽  
Courtney A. Balliro ◽  
Firas El-Khatib ◽  
Michele M. Maheno ◽  
Mallory A. Hillard ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Accuracy Comparison ◽  
Freestyle Libre ◽  
Monitoring Devices

PDB40 Eliciting Patient Preferences for Continuous Glucose Monitoring Devices in Type 1 Diabetes

2021 ◽  
Vol 24 ◽  
pp. S85
Author(s):  
K. Hannah ◽  
R. Lich ◽  
K. Nair ◽  
H.D. Anderson ◽  
S. Ellis ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Patient Preferences ◽  
Glucose Monitoring ◽  
Monitoring Devices

scholarly journals Fifteen-minute consultation: Practical use of continuous glucose monitoring

2021 ◽  
pp. edpract-2020-321190
Author(s):  
Astha Soni ◽  
Neil Wright ◽  
Juliana Chizo Agwu ◽  
Josephine Drew ◽  
Melanie Kershaw ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Continuous Glucose Monitoring ◽  
Diabetes Management ◽  
Glucose Monitoring ◽  
Children And Young People ◽  
Use Of Technology ◽  
Finger Prick ◽  
Monitoring Devices

Type 1 diabetes is a self-managed condition. Regular monitoring of blood glucose (BG) levels has been the cornerstone of diabetes management. Finger prick BG testing traditionally has been the standard method employed. More recently, rapid advancements in the development of continuous glucose monitoring devices have led to increased use of technology to help children and young people with diabetes manage their condition. These devices have the potential to improve diabetes control and reduce hypoglycaemia especially if used in conjunction with a pump to automate insulin delivery. This paper aims to provide an update on main CGM devices available and practical considerations for doctors if they come across a child with diabetes who is using one of these devices.

scholarly journals Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice

2021 ◽  
Author(s):  
Carol H Wysham ◽  
Davida F Kruger
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Treatment Adherence ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Treatment Regimens ◽  
Freestyle Libre ◽  
The Us

Abstract Use of continuous glucose monitoring (CGM) has been shown to improve clinical outcomes in type 1 diabetes (T1D) and type 2 diabetes (T2D), including improved glycemic control, better treatment adherence and an increased understanding of their treatment regimens. Retrospective analysis of CGM data allows clinicians and patients to identify glycemic patterns that support and facilitate informed therapy adjustments. There are currently two types of CGM systems: real-time CGM (rtCGM) and flash CGM. The FreeStyle Libre 2 (FLS2) is the newest flash CGM system commercially available. Because the FLS2 system was only recently cleared for use in the US, many endocrinologists and diabetes specialists may be unfamiliar with strengths, limitations and potential of the FSL2 system. This article focuses on practical approaches and strategies for initiating and using flash CGM in endocrinology and diabetes specialty practices.

scholarly journals Study protocol for optimising glycaemic control in type 1 diabetes treated with multiple daily insulin injections: intermittently scanned continuous glucose monitoring, carbohydrate counting with automated bolus calculation, or both? A randomised controlled trial

BMJ Open ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. e036474
Author(s):  
Anna Lilja Secher ◽  
Ulrik Pedersen-Bjergaard ◽  
Ole Lander Svendsen ◽  
Birthe Gade-Rasmussen ◽  
Thomas P Almdal ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Randomised Controlled Trial ◽  
Continuous Glucose Monitoring ◽  
Standard Care ◽  
Controlled Trial ◽  
Glucose Monitoring ◽  
Carbohydrate Counting ◽  
Freestyle Libre ◽  
Randomised Controlled

IntroductionThere are beneficial effects of advanced carbohydrate counting with an automatic bolus calculator (ABC) and intermittently scanned continuous glucose monitoring (isCGM) in persons with type 1 diabetes. We aim to compare the effects of isCGM, training in carbohydrate counting with ABC and the combination of the two concepts with standard care.Methods and analysisA multi-centre randomised controlled trial with inclusion criteria: ≥18 years, type 1 diabetes ≥1 year, injection therapy, HbA1c >53 mmol/mol, whereas daily use of carbohydrate counting and/or CGM/isCGM wear are exclusion criteria. Inclusion was initiated in October 2018 and is ongoing. Eligible persons are randomised into four groups: standard care, ABC, isCGM or ABC+isCGM. Devices used are FreeStyle Libre Flash and smart phone diabetes application mySugr. Participants attend group courses according to treatment allocation with different educational contents. Participants are followed for 26 weeks with clinical visits and telephone consultations. At baseline and at study end, participants wear blinded CGM, have blood samples performed and fill in questionnaires on person-related outcomes, and at baseline also on personality traits and hypoglycaemia awareness. The primary outcome is the difference in time spent in normoglycaemia (4–10 mmol/L) at study end versus baseline between the isCGM group and the standard care group. Secondary outcomes will also be analysed. Results are expected in 2020.Ethics and disseminationRegional Scientific Ethics Committee approval (H-17040573). Results will be sought disseminated at conferences and in high impact journals.Trial registration numberClinicalTrial.gov registry (NCT03682237).

scholarly journals Glycemic Variability and Hypoglycemic Excursions With Continuous Glucose Monitoring Compared to Intermittently Scanned Continuous Glucose Monitoring in Adults With Highest Risk Type 1 Diabetes

2019 ◽  
Vol 14 (3) ◽  
pp. 567-574 ◽  
Author(s):  
Parizad Avari ◽  
Vanessa Moscardo ◽  
Narvada Jugnee ◽  
Nick Oliver ◽  
Monika Reddy
Keyword(s):  
Type 1 Diabetes ◽  
High Risk ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Severe Hypoglycemia ◽  
Glycemic Variability ◽  
Clinical Trial Registration ◽  
Freestyle Libre ◽  
The Impact

Background: The I-HART CGM study has shown that real-time continuous glucose monitoring (rtCGM) has greater beneficial impact on hypoglycemia than intermittently scanned continuous glucose monitoring (iscCGM) in adults with type 1 diabetes at high risk (Gold score ≥4 or recent severe hypoglycemia using insulin injections). In this subanalysis, we present the impact of rtCGM and iscCGM on glycemic variability (GV). Methods: Forty participants were recruited to this parallel group study. Following two weeks of blinded rtCGM (DexcomG4), participants were randomized to rtCGM (Dexcom G5; n = 20) or iscCGM (Freestyle Libre; n = 20) for eight weeks. An open-extension phase enabled participants on rtCGM to continue for a further eight weeks and those on iscCGM to switch to rtCGM over this period. Glycemic variability measures at baseline, 8- and 16-week endpoints were compared between groups. Results: At the eight-week endpoint, between-group differences demonstrated significant reduction in several GV measures with rtCGM compared to iscCGM (GRADE%hypoglycemia, index of glycemic control [IGC], and average daily risk range [ADRR]; P < .05). Intermittently scanned continuous glucose monitoring reduced mean average glucose and glycemic variability percentage and GRADE%hyperglycemia compared with rtCGM ( P < .05). At 16 weeks, the iscCGM group switching to rtCGM showed significant improvement in GRADE%hypoglycemia, personal glycemic status, IGC, and ADRR. Conclusion: Our data suggest most, but not all, GV measures improve with rtCGM compared with iscCGM, particularly those measures associated with the risk of hypoglycemia. Selecting appropriate glucose monitoring technology to address GV in this high-risk cohort is important to minimize the risk of glucose extremes and severe hypoglycemia. Clinical trial registration: ClinicalTrials.gov NCT03028220

Sign in / Sign up

Export Citation Format

Share Document